ロード中...
Rho-Associated Protein Kinase Inhibitor Treatment Promotes Proliferation and Phagocytosis in Trabecular Meshwork Cells
PurposeContinuous reductions in trabecular meshwork (TM) cellularity inhibit aqueous humor (AH) outflow, which is the main cause of primary open-angle glaucoma. Rho-associated protein kinase inhibitor (ROCKi) targets the TM to reduce intraocular pressure (IOP) and increase AH outflow facility. Howev...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2020-03-01
|
| シリーズ: | Frontiers in Pharmacology |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/article/10.3389/fphar.2020.00302/full |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|